The firms will evaluate two adjuvant treatment options, Datroway with rilvegostomig or rilvegostomig monotherapy, against standard-of-care treatment.

European stock markets closed mixed Friday as the Stoxx Europe 60 rose 0.11%, Germany's DAX 40 eased 0.07%, the FTSE 100 in London gained 0.31%, France's CAC 40 rose 0.11% and the Swiss Market Index ...

The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1. Okuzawa is currently Daiichi’s chief operating officer.

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its ...

AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as chief executive officer from 1 April 2025.

Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in ...